Increased values of the circulating PDGFβ sustains the "withdrawal syndrome" after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia

Blood Cells Mol Dis. 2015 Oct;55(3):211-2. doi: 10.1016/j.bcmd.2015.06.010. Epub 2015 Jun 23.

Authors

Sara Galimberti¹, Giulia Fontanelli², Sara Barsotti², Federica Ricci², Francesca Guerrini², Claudia Baratè²

Affiliations

¹ Department of Clinical and Experimental Medicine, Section of Hematology - University of Pisa, Pisa, Italy. Electronic address: [email protected].
² Department of Clinical and Experimental Medicine, Section of Hematology - University of Pisa, Pisa, Italy.

PMID: 26227847
DOI: 10.1016/j.bcmd.2015.06.010

No abstract available

Publication types

Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Middle Aged
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Proto-Oncogene Proteins c-sis / metabolism*
Receptor, Platelet-Derived Growth Factor beta / blood*
Substance Withdrawal Syndrome / blood*
Substance Withdrawal Syndrome / etiology

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-sis
Protein-Tyrosine Kinases
Receptor, Platelet-Derived Growth Factor beta